Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Hepatocellular Carcinoma, Pancreatic Duc...
Phase PHASE1
Enrollment 325
Locations 54 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy), cohort 9 receives ABBV-400 with a strong CYP3A3 inhibitor (ITZ), and cohort 10 receives ABBV-400 with bevacizumab. All cohorts are followed by a safety follow-up period. Approximately 325 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive \[HR+\]/HER2-breast cancer \[BC\]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide. In cohorts 1-8, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+/HER2-BC, HNSCC, and PROC/primary peritoneal/fallopian tube cancer will receive intravenous (IV) ABBV-400 monotherapy, in cohort 9 participants will receive IV ABBV-400 and an oral solution of ITZ, and in cohort 10 participants will receive IV ABBV-400 and IV bevacizumab, for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ABBV-400 — Intravenous (IV) Infusion
  • Drug: Itraconazole (ITZ) — Oral Solution
  • Drug: Bevacizumab — IV Infusion

Primary Outcomes

  • Objective Response Rate (ORR) (Up to 36 Months)
  • Number of Participants with Adverse Events (AEs) (Up to 36 Months)
  • Maximum Observed Concentration (Cmax) of ABBV-400 Conjugate (Up to 36 Months)
  • AUC from Time 0 to the End of Dosing Interval (AUCtau) of ABBV-400 Conjugate (Up to 36 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-11-09
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 325 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AbbVie
Principal Investigators:
  • ABBVIE INC. (STUDY_DIRECTOR) - AbbVie
Contact Information
Study Contact:
ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com
HOPE Team
210-593-5250
hopeteam@startresearch.com
START-San Antonio
Dr. Papadopoulos
START-San Antonio
Interventions
  • Drug: ABBV-400 — Intravenous (IV) Infusion
  • Drug: Itraconazole (ITZ) — Oral Solution
  • Drug: Bevacizumab — IV Infusion
Study Locations (54 sites)
City of Hope National Medical Center /ID# 258645, Duarte, California 91010 United States
UCSF Medical Center - Mount Zion /ID# 257705, San Francisco, California 94115 United States
University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128, Aurora, Colorado 80045-7158 United States
Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926, Denver, Colorado 80218 United States
Florida Cancer Specialists /ID# 261569, Sarasota, Florida 34232 United States
Northwestern University Feinberg School of Medicine /ID# 257378, Chicago, Illinois 60611-2927 United States
University of Chicago Medical Center /ID# 258197, Chicago, Illinois 60637 United States
START Midwest /ID# 256581, Grand Rapids, Michigan 49546-7062 United States
Washington University-School of Medicine /ID# 257379, St Louis, Missouri 63110 United States
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Laboratory values meeting the criteria laid out in the protocol. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Documented diagnosis of locally advanced or metastatic hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), squamous cell carcinoma of the esophagus, (ESCC), triple negative breast cancer (TNBC), hormone receptor+/HER2-breast cancer (HR+/HER2-BC), head and neck squamous-cell-carcinoma (HNSCC), or Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer (by World Health Organization \[WHO\] criteria). Participant meets the criteria for disease activity laid out in the protocol. Exclusion Criteria: * Have received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400. Palliative radiation therapy for bone, skin, or subcutaneous metastases with 10 fractions or less is permitted and not subject to a washout period. * Unresolved clinically significant AEs \> Grade 1 from prior anticancer therapy. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis, including but not limited to those listed in the protocol. * History of clinically significant, intercurrent lung-specific illnesses, including those laid out in the protocol. * Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue on antiepileptic therapy if required. * History of other active malignancy, with the exception of those laid out in the protocol. * Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at screening (i.e., rheumatoid arthritis, Sjogren's, sarcoidosis etc.), and prior pneumonectomy.
Conditions Breast Cancer
Phase NA
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Procedure: core needle biopsy — Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
  • Other: blood draw — blood draw

Primary Outcomes

  • assess the change in Ki67 (baseline to at least 2 weeks of endocrine therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-30
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Minna Lee, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Minna Lee, MD
646-888-6898
leem15@mskcc.org
Komal Jhaveri, MD
646-888-5157
Minna Lee, MD
646-888-6898
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Interventions
  • Procedure: core needle biopsy — Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
  • Other: blood draw — blood draw
Study Locations (1 sites)
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women aged ≥18 years with biopsy-proven stage I-III invasive breast cancer that is ER+/HER2- * Scheduled to undergo upfront surgery * Eligible for genetic testing in accordance with National Comprehensive Cancer Network guidelines(BRCA2 arm only) Exclusion Criteria: * History of breast cancer * Receipt of ET for risk reduction in the previous 3 months * Stage IV disease at presentation * Scheduled to undergo neoadjuvant systemic chemotherapy * Pregnant
Conditions Adenine Phosphoribosyltransferase Defici...
Phase Not Applicable
Enrollment 35000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: * Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. * Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better. * Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Facilitate translational and epidemiological research (2009-2039)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2009-11-06
Completion: 2039-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 35000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UK Kidney Association
Contact Information
Study Contact:
Zoe Plummer
zoe.plummer@ukkidney.org
Zoe Plummer, Dr
zoe.plummer@ukkidney.org
Zoe Plummer
Interventions
N/A
Study Locations (1 sites)
Zoe Plummer, Bristol, South West BS34 7RR United Kingdom
Eligibility Criteria
* Kidney Rare Disease * Paeds and adults * Eligibility differs for each rare disease group * See: https://ukkidney.org/rare-renal/recruitment
Conditions Alcohol Use Disorder, Anxiety, Depressio...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The proposed study consists of two phases. During Phase 1, the investigators will recruit a small sample of participants to complete a psychosocial intervention termed Amplification of Positivity (AMP) for individuals experiencing comorbid depression or anxiety disorders and alcohol use disorder (AMP-A). These participants will be asked to provide both qualitative and quantitative input about the AMP-A intervention. Based on their input and clinician input, the AMP-A manual will be modified for use in Phase 2. The goal is to recruit up to 20 participants in order to ensure there will be at least 8 participants who complete all sessions of AMP-A. Phase 2 is a randomized clinical trial (RCT) protocol in which individuals experiencing comorbid depression or anxiety disorders and alcohol use disorder will be randomized to complete AMP-A or an evidence-based cognitive-behavioral therapy (CBT) intervention. Up to 100 participants will be recruited in order to reach a target of N=60. Assessed outcomes will include participant acceptability and completion rates, participant compliance with the intervention, positive and negative affect, substance use- and depression and anxiety-related symptom severity, functional disability, and neural reactivity to reward and alcohol cues during functional magnetic resonance imaging (fMRI).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy — Cognitive Behavioral Therapy
  • Behavioral: Amplification of Positivity Therapy — Amplification of Positivity Therapy
  • Behavioral: Surveys and Interviews — Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.

Primary Outcomes

  • Perceived acceptability and satisfaction of the intervention as measured with the Adherence and Acceptability Scale (AAS) (Average of total scores from the following time points: pre-treatment, 2 weeks after starting treatment, 6 weeks after starting treatment, and at post-treatment (average of 16 weeks after baseline assessment))
  • Change in positive affect self-report measured with National Institute of Health (NIH) Patient Reported Outcome Measurement and Information System (PROMIS) Positive Affect score (Trajectory of change from pre-treatment to post-treatment (last time point assessed on average 16 weeks after baseline assessment))
  • Change in number of drinking days in the past month (Trajectory of change from pre-treatment to post-treatment (last time point assessed on average 16 weeks after baseline assessment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-25
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laureate Institute for Brain Research, Inc.
Collaborators: University of California, San Diego, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigators:
  • Robin L Aupperle, PhD (PRINCIPAL_INVESTIGATOR) - Laureate Institute for Brain Research
Contact Information
Study Contact:
Robin L Aupperle, PhD
918-502-5155
neurocatt@laureateinstitute.org
Robin L Aupperle, PhD
918-502-5155
neurocatt@laureateinstitute.org
Laureate Institute for Brain Research
Interventions
  • Behavioral: Cognitive Behavioral Therapy — Cognitive Behavioral Therapy
  • Behavioral: Amplification of Positivity Therapy — Amplification of Positivity Therapy
  • Behavioral: Surveys and Interviews — Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
Study Locations (1 sites)
Laureate Institute for Brain Research, Tulsa, Oklahoma 74008 United States
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 65 years old. 2. Meeting diagnostic criteria for alcohol use disorder 42 according to the DSM-5. 3. Reports that they would like to seek treatment for AUD and that AUD is one of the primary challenges they would like to address in treatment. 4. Phase 1: Significant depression or anxiety symptoms as indexed by scoring Patient Health Questionnaire (PHQ-9) ≥ 10 and/or Overall Anxiety Severity and Impairment Scale (OASIS) ≥ 8. Phase 2: Significant depression or anxiety symptoms as indexed by scoring ≥ 55 on either of the NIH PROMIS ((Patient-Reported Outcomes Measurement Information System) Depression and/or Anxiety scales. 5. Below normative levels of positive affect as indexed by PROMIS Positive Affect \<50. 6. Able to provide written informed consent. 7. Have sufficient proficiency in the English language to understand and complete interviews, questionnaires, and all other study procedures. Exclusion Criteria: 1. Unwillingness or inability to complete any of the major aspects of the study protocol, including self-report or behavioral assessment. However, failing to complete some individual aspects of these assessment sessions will be acceptable (i.e., being unwilling to answer individual items on some questionnaires or being unwilling to complete a behavioral task). In addition, the neuroimaging portion of the protocol will be optional. 2. Non-correctable vision or hearing problems that interfere with the participant's ability to complete study assessments. 3. No telephone or easy access to telephone. 4. Diagnosis of Schizophrenia spectrum, other psychotic disorders, obsessive-compulsive disorder, eating disorders, substance use disorders within the past year other than alcohol use disorder or cannabis use disorder, or bipolar I disorder. Mild binge eating disorder will be considered for inclusion on a case-by-case basis at the discretion of the PI. 5. Active suicidal ideation with plan and intent to attempt suicide within the next month. 6. Has a history of unstable liver or renal insufficiency; glaucoma; significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbance; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments. 7. A positive test for drugs of abuse, including alcohol (breath test) and substances of dependence that are not physician prescribed (i.e., cocaine, cannabis, opioids, stimulants).at the time of baseline assessments. Participants will be asked to refrain from using alcohol within 24 hours prior to assessment sessions and to refrain from using marijuana within 48 hours of assessment sessions. 8. Current use of a medication within the 6 weeks prior to enrolling in the study that could potentially affect brain functioning and/or the positive valence system (e.g., anxiolytics, antipsychotics, mood stabilizers, opioid antagonists such as naltrexone or other medications specifically targeting alcohol use or cravings). The current use of antidepressants (i.e., SSRIs), benzodiazepines, and psychostimulants will not be excluded as long as the dose has remained consistent for 6 weeks prior to baseline assessment sessions. Individuals who are on stable doses (≥ 6 weeks) of mood stabilizers or antipsychotics may be included if it is determined that they are being prescribed for purposes of treating unipolar depression or anxiety. Inclusion of individuals reporting other types of medications or supplements not listed or considered this far will be at the discretion of the PI according to evidence in the literature of it affecting brain function or brain blood flow. 9. Taking drugs that affect the fMRI hemodynamic response (e.g., methylphenidate, acetazolamide, and excessive caffeine intake \> 1000 mg/day) - Phase 2 only 10. Concurrent engagement in psychosocial treatments that specifically target alcohol use disorder or mood/anxiety symptoms and began within 12 weeks of baseline assessments. Individuals concurrently receiving psychosocial treatments for other symptoms, or that are not specifically targeting symptoms (e.g., ongoing support groups) will not be excluded as long as the dose of treatment (i.e., frequency of sessions) has not changed significantly within 6 weeks prior to enrolling in the study. 11. MRI contraindications (for those in Phase 2 opting into this portion) including: cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60-120 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy - Phase 2 only 12. Moderate to severe traumatic brain injury (\>30 min. loss of consciousness or \>24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits, neurological disorders, or severe or unstable medical conditions that might be compromised by participation in the study (to be determined by primary care provider). 13. Severity of alcohol use disorder requiring more intensive treatment (i.e., intensive outpatient or residential), as determined by licensed clinician determination of American Society of Addiction Medicine (ASAM) Criteria ≥ 0-1 across dimensions, with the exception of a '2' on the emotional dimension. 14. Given the current study involves development of the positive affect intervention, we will not enroll any special vulnerable populations (pregnant women, fetuses, neonates, prisoners, children).
Conditions Breast Cancer, Breast Carcinoma in Situ,...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to evaluate the outcomes of two standard of care group exercise regimens to increase muscle mass in women who have been treated with breast cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Control Arm ACSM Guidelines — The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
  • Other: Experimental Arm 6-12-25 repetitions per set — The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.

Primary Outcomes

  • Determine changes in muscle and fat mass during and after each exercise regimen (The exercise program will last for 8 weeks and continuously monitored by the PI and clinical team.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-09
Completion: 2027-01
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Principal Investigators:
  • Colin Champ, MD, CSCS (PRINCIPAL_INVESTIGATOR) - Radiation Oncologist
Contact Information
Study Contact:
Clinical Trials Contact
4123306151
clinicaltrials@ahn.org
Clinical Trials Contact
clinicaltrials@ahn.org
Allegheny General Hospital
Interventions
  • Other: Control Arm ACSM Guidelines — The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
  • Other: Experimental Arm 6-12-25 repetitions per set — The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
Study Locations (1 sites)
Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States
Eligibility Criteria
Inclusion Criteria: Age 20-89 years * Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast * Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed. Exclusion Criteria: * Any current treatment with cytotoxic chemotherapy for breast cancer * Inability to safely engage in group sessions of resistance training as deemed by study PI * Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
Conditions Triple Negative Breast Cancer, Diffuse L...
Phase PHASE1
Enrollment 168
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ONM-501 — Intratumoral injection
  • Drug: Cemiplimab — Intravenous administration of 350 mg

Primary Outcomes

  • Dose Escalation and Expansion Phases: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity (Up to approximately 24 months)
  • Dose Escalation and Expansion Phases: Number of Participants with Dose-Limiting Toxicities (DLTs) (Up to approximately 24 months)
  • Dose Escalation and Expansion Phases: Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-10-13
Completion: 2026-08-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 168 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: OncoNano Medicine, Inc.
Contact Information
Study Contact:
Trials@OncoNanoMed.com
(682) 285-1411
trials@onconanomed.com
Jia (Jenny) Liu, MD
+61293555633
SVHS.CancerResearch@svha.org.au
St Vincent's Hospital
Jia (Jenny) Liu, MD
St Vincent's Hospital
Interventions
  • Drug: ONM-501 — Intratumoral injection
  • Drug: Cemiplimab — Intravenous administration of 350 mg
Study Locations (16 sites)
California Research Institute, Los Angeles, California 90027 United States
BRCR Global, Tamarac, Florida 33321 United States
Gabrail Cancer Center Research, Canton, Ohio 44718 United States
Ohio State University, Columbus, Ohio 43210 United States
Allegheny Health Network, Pittsburgh, Pennsylvania 15224 United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232 United States
University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
MD Anderson Cancer Center, Houston, Texas 77030 United States
Virginia Cancer Specialists, PC, Fairfax, Virginia 22031 United States
St Vincent's Hospital, Darlinghurst, New South Wales 2010 Australia
Eligibility Criteria
Inclusion Criteria: 1. Ability to understand and willingness to sign written informed consent before performance of any study procedures 2. Age ≥ 18 years 3. Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists. 4. Participants must have a minimum of one injectable and measurable lesion. 5. Participants with prior Hepatitis B or C are eligible if they have adequate liver function 6. Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load \<400 copies/mL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells/uL 7. Adequate bone marrow function: 8. Adequate liver function Exclusion Criteria: Patients will be excluded from this study if they meet any of the following criteria (Part 1a and Part 1b). 1. Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy. 2. Major surgery within 4 weeks before the first dose of study drug. 3. Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion. 4. Prolongation of corrected QT (QTc) interval to \>470 millisecond (ms) for males and females when electrolytes balance is normal. 5. Females who are breastfeeding or pregnant at screening or baseline 6. Females of childbearing potential that refuse to use a highly effective method of contraception. 7. Has uncontrolled or poorly controlled hypertension as defined by a sustained BP \> 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter. 8. Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501 9. Has an active infection requiring systemic treatment 10. Is participating in another therapeutic clinical trial Additional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b) 1. Has known hypersensitivity to any component in the formulation of cemiplimab 2. Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (\>10 mg daily prednisone equivalent) 3. Has a condition requiring systemic treatment with corticosteroids
Conditions Metastatic Breast Cancer, Advanced Breas...
Phase PHASE3
Enrollment 495
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

IMPORTANT study is a multicenter, open-label, prospective, randomized-controlled, non-inferiority trial with a pragmatic approach involving older patients (≥ 70 years old) with advanced hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, not amenable for curative treatment and without prior therapy for advanced disease, who are suitable to receive CDK 4/6-inhibitors plus endocrine therapy as first line therapy. The study implements two approaches with high level of evidence, namely the use of comprehensive geriatric assessment (CGA) approach in treatment decision making and the use of CDK 4/6-inhibitors as the initial treatment of choice, to investigate whether a common clinical practice (starting dose reduction of CDK 4/6-inhibitors in older patients) with evidence of low certainty can be standardized using a more individualized-based approach. On the basis of baseline CGA assessment, patients will either receive full dose of CDK 4/6-inhibitors plus endocrine therapy (if patients are fit according to CGA) or be randomized to full dose vs. reduced initial dose of CDK 4/6-inhibitors (if vulnerable or frail according to CGA). The study hypothesis is that adjusting the dose according to vulnerability will allow patients to tolerate treatment better without jeopardizing the treatment efficacy. This project has received funding from the European Union's HORIZON 2022 research and innovation actions supporting the implementation of the Mission on Cancer under grant agreement No 101104589.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CDK 4/6 inhibitors — Either Palbociclib, Ribociclib or Abemaciclib
  • Drug: Endocrine therapy — Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor

Primary Outcomes

  • Time to treatment failure (Up to 5 years from treatment initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-04-01
Completion: 2029-05-31
Eligibility
Age: 70 Years and older
Sex: ALL
Volunteers: false
Enrollment: 495 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Örebro County
Collaborators: University of Patras, University of Florence, Azienda USL Toscana Centro, Helsinki University Central Hospital, Institute for Medical Technology Assessment - the Netherlands, Security Labs Consulting Limited, Circular Economy Foundation, Universidad Nacional de Educación a Distancia, Hellenic Cooperative Oncology Group, University Hospital, Akershus, Uppsala County Council, Sweden, Hospital Clinic of Barcelona, Phaze Clinical Research & Pharma Consulting, Bröstcancerförbundet, Eunomia Ltd, University of Applied Sciences and Arts Northwestern Switzerland, CareAcross, Örebro University, Sweden
Principal Investigators:
  • Antonios Valachis, Assoc Prof (STUDY_CHAIR) - Region Örebro län
Contact Information
Study Contact:
Antonios Valachis, Assoc Prof
+46196021792
important@oru.se
Peeter Karihtala, Prof
peeter.karihtala@hus.fi
Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
Helena Linardou, Dr
elinardou@otenet.gr
Fourth Oncology Department & Comprehensive Clinical Trials Center, Metropolitan Hospital
Interventions
  • Drug: CDK 4/6 inhibitors — Either Palbociclib, Ribociclib or Abemaciclib
  • Drug: Endocrine therapy — Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
Study Locations (12 sites)
Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland
Fourth Oncology Department & Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, Greece
Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece
Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Pátrai, Greece
Medical Oncology Unit, S. Andrew Hospital, Pátrai, Greece
Second Department of Medical Oncology, Euromedica General Clinic, Thessaloniki, Greece
Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
"Sandro Pitigliani" Department of Medical Oncology, Hospital of Prato, Prato, Italy
Department of Oncology, Akershus University Hospital (AHUS), Oslo, Norway
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
Eligibility Criteria
Inclusion Criteria: The following inclusion criteria will be applied: 1. Patients male or female aged at least 70 years old at the time of informed consent. 2. Histologically or cytologically confirmed diagnosis of HR-positive (defined as estrogen-receptor ≥ 1%), HER2-negative breast cancer according to analysis of the most recent tumor specimen by local laboratory. 3. Advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative treatment. 4. No prior systemic treatment for advanced disease (recurrence during neo-/adjuvant endocrine therapy is allowed). A prior period of treatment with aromatase inhibitors or fulvestrant for up to 28 days from the CDK 4/6-inhibitor initiation is allowed. 5. Adjuvant treatment with CDK 4/6-inhibitors is allowed provided a disease-free interval from treatment end \>12 months. 6. Either measurable disease or non-measurable bone only disease, but evaluable according to RECIST criteria 1.1. 7. Written informed consent prior to any study-specific procedures. 8. Adequate organ function as defined in the summary of product characteristics (SmPC) for the CDK 4/6-inhibitors that is planned to be used. 9. Able to swallow capsules. 10. Able to understand and consent in English language or in native language for each participating country. Exclusion Criteria: Eligible patients will be excluded if they have one of the following criteria: 1. Patients considered from treating physician as non-suitable for treatment with CDK 4/6-inhibitors. 2. Contraindications according to SmPC for the CDK 4/6-inhibitors that is planned to be used. 3. Presence of visceral crisis, lymphangitis carcinomatosis, or leptomeningeal carcinomatosis. 4. History of any other cancer (except of non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years. 5. Participating in other interventional trial.

Strength After Breast Cancer

NCT06052488
Recruiting
Conditions Breast Cancer
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: * Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find the program practical? * What are the barriers to and facilitators of delivering the group exercise program in a clinical setting and what changes need to be made to the program to improve sustainability and to facilitate implementation at other clinical sites? Participants will complete study questionnaires before and after engaging in the group exercise program and they will participate in interviews following participation in the program.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Strength After Breast Cancer — Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist

Primary Outcomes

  • Screening Rate (At screening)
  • Eligibility Rate (At screening)
  • Enrollment Rate (At screening)
  • Program completion rate (Up to 2 months)
  • Intervention session completion rate (Up to 2 months)
  • Assessment completion rate (Up to 5 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-02
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MGH Institute of Health Professions
Principal Investigators:
  • Stephen Wechsler, DPT, PhD (PRINCIPAL_INVESTIGATOR) - MGH Institute of Health Professions
Contact Information
Study Contact:
Stephen Wechsler, DPT, PhD
774-217-3221
swechsler@mghihp.edu
Kathleen Lyons, ScD, OTR/L
klyons2@mghihp.edu
Stephen Wechsler, DPT, PhD
774-217-3221
swechsler@mghihp.edu
MGH Institute of Health Professions
Interventions
  • Behavioral: Strength After Breast Cancer — Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
Study Locations (1 sites)
MGH Institute of Health Professions, Boston, Massachusetts 02129 United States
Eligibility Criteria
Inclusion Criteria: * ≥18 years of age * Diagnosed with Stage I-III breast cancer, having completed primary cancer treatment (e.g., surgery, chemotherapy, radiation therapy); hormonal therapies and adjuvant targeted therapies will be permitted Exclusion Criteria: * Any injury or medical condition that would prohibit being able to safely perform exercise as indicated by the Physical Activity Readiness Questionnaire (i.e., atrial fibrillation, chest pain or angina, uncontrolled high blood pressure or hypertension, loss of balance due to dizziness in the past 12 months, or loss of consciousness in the past 12 months). * Non-English speaking
Conditions Breast Cancer, Colorectal Cancer, Lung C...
Phase NA
Enrollment 130
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for connecting older adults with depressed mood to mental health services with the Open Door for Cancer (OD-C) approach. We will find out if the OD-C approach is practical and useful for cancer patients who participate in the intervention and for providers who see or treat cancer patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Questionnaires — Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
  • Other: Interviews — Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
  • Other: 30-minute telephone or videoconference sessions — Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are: 1. Provide education about depression and treatment options 2. Identify treatment preferences and a personal goal achievable with mental health care 3. Assess barriers to treatment initiation 4. Recommend a referral using standardized referral options 5. Address barriers to accessing care

Primary Outcomes

  • Refusal rates (2 years)
  • Attrition rates (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-07
Completion: 2026-09
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Weill Medical College of Cornell University
Principal Investigators:
  • Kelly McConnell, PhD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Kelly McConnell, PhD
646-888-0026
mcconnek@mskcc.org
Christian Nelson, PhD
646-888-0030
Kelly McDonnell, PhD
646-888-0026
Memorial Sloan Kettering Cancer Center
Interventions
  • Other: Questionnaires — Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
  • Other: Interviews — Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
  • Other: 30-minute telephone or videoconference sessions — Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are: 1. Provide education about depression and treatment options 2. Identify treatment preferences and a personal goal achievable with mental health care 3. Assess barriers to treatment initiation 4. Recommend a referral using standardized referral options 5. Address barriers to accessing care
Study Locations (1 sites)
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: Patients * Per medical record and/or self-report, diagnosed with breast, colorectal, lung, or prostate cancer at age 65 years or older * Per medical record and/or self-report, undergoing active cancer treatment (e.g., radiation, chemotherapy, immunotherapy, surgery) or within six months of completing treatment * Score of ≥5 on the Patient Health Questionnaire-9 (PHQ-9) * Per self-report, fluent in English\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study: 1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English) Providers * Per self-report, works in oncology, nursing, social work, psychology, or psychiatry * Per self-report, currently works in oncology at least 50% of the time * Per self-report, provided cancer care for at least three years at time of consent * Per self-report, fluent in English Exclusion Criteria: Patients * Severely cognitively impaired as demonstrated by Blessed Orientation Memory Concentration scores of ≥ 11 * Per research staff judgment and/or self-report, too ill or weak to complete study procedures * Per medical record and/or self-report, receiving hospice care at the time of enrollment * Per medical record and/or self-report, currently enrolled in mental health treatment Providers * N/A
Conditions Asthma
Phase PHASE3
Enrollment 231
Locations 147 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Biological: Tezepelumab — Participants will be receiving subcutaneous injection of tezepelumab
  • Other: Placebo — Participants will be receiving subcutaneous injection of matching placebo

Primary Outcomes

  • Annualized severe asthma exacerbation rate (AAER) (From Baseline to Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-08-24
Completion: 2030-08-23
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: false
Enrollment: 231 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Collaborators: Amgen
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Biological: Tezepelumab — Participants will be receiving subcutaneous injection of tezepelumab
  • Other: Placebo — Participants will be receiving subcutaneous injection of matching placebo
Study Locations (147 sites)
Research Site, Montgomery, Alabama 36106 United States
Research Site, Phoenix, Arizona 85016 United States
Research Site, Little Rock, Arkansas 72202 United States
Research Site, La Jolla, California 92037 United States
Research Site, Long Beach, California 90806 United States
Research Site, Orange, California 92868 United States
Research Site, San Diego, California 92123 United States
Research Site, Atlanta, Georgia 30322 United States
Research Site, Savannah, Georgia 31406 United States
Research Site, Baltimore, Maryland 21287 United States
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent from (ICF) at least one parent/caregiver (as per local guidelines) and accompanying informed assent from the participant (where the participant is able to provide assent) prior to admission to the study. 2. Participants must be 5 to \< 12 years of age, at the time of signing the assent form (as applicable per local guidelines) and their caregivers signing the ICF and at Visit 3. 3. Documented physician diagnosis of severe asthma confirmed and evaluated for at least 6 months prior to Visit 1. 4. Documented physician-prescribed treatment with a total daily dose of either medium or high dose, for at least 3 months with stable dose ≥ 1 month prior to Visit 1. 5. Documented treatment with at least one additional maintenance asthma controller medication is required according to local guidelines and standard of care; (long-acting beta agonist, leukotriene receptor antagonist, long-acting muscarinic antagonist) for at least 3 months with stable dose ≥ 1 month prior to Visit 1. 6. Supportive evidence of asthma as documented by one of the following: 1. Post-BD (albuterol/salbutamol) responsiveness of FEV1 ≥ 10% during Screening (15 to 30 min after administration of 4 puffs of albuterol/salbutamol with a maximum of 12 puffs of reliever medication only if tolerated by the participant) at either Visit 1 or Visit 2. If (a) is not achieved at Visit 1 or Visit 2, historical documentation by any of the below prior to Visit 1: 2. Post-BD responsiveness of FEV1 ≥ 10%. 3. Positive methacholine challenge defined as provocative concentration (PC20) of ≤ 16 mg/mL. 4. PEF average daily diurnal variability \> 13% over a 2-week period. 5. Variability of FEV1 ≥ 12% between any two clinical visits. 6. Positive exercise challenge test (defined as a fall in FEV1 of \> 12%). 7. FeNO ≥ 20 ppb despite confirmed ICS maintenance therapy. 7. History of at least 2 severe asthma exacerbation events OR 1 severe asthma exacerbation event resulting in hospitalisation within 12 months prior to Visit 1. 8. Pre-BD FEV1 \>50% and ≤ 95%PN OR FEV1/forced vital capacity (FVC) ratio ≤ 0.85 at either Visit 1 or Visit 2. 9. Evidence of uncontrolled asthma, with at least 1 of the below criteria: 1. ACQ-IA score ≥ 1.5 at least once during Screening/Run-in, including Visit 3 (prior to Randomisation) for participants ≥ 6 years old at Screening. 2. Use of reliever medication, other than as a preventive for exercise induced bronchospasm, on 3 or more days per week for at least 1 week during the Screening/Run-in period. 3. Sleep awakening due to asthma symptoms requiring use of reliever medication at least once during the Screening/Run-in period. 4. Asthma symptoms 3 or more days per week in at least 1 week during the Screening/Run-in period. 10. Body weight ≥ 16 kg at Visit 1 (Screening) and Visit 3 (Randomisation). Exclusion Criteria: 1. History of vocal cord dysfunction, cystic fibrosis, primary ciliary dyskinesia, or chronic rhinosinusitis with nasal polyposis. 2. History of any clinically significant disease or disorder other than asthma which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. 3. History of a clinically significant deterioration in asthma or asthma exacerbation including those requiring use of systemic corticosteroids or increase in the maintenance dose of oral corticosteroids within 30 days prior to Visit 1. 4. Change in ICS dose within 1 month prior to Visit 1. 5. History of a life-threatening asthma exacerbation resulting in a hypoxic seizure or requiring intubation.
Conditions Blood Pressure
Phase NA
Enrollment 1440
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study seeks to develop the evidence for a sustainable, community-partnered, multi-level health system strategy to improve blood pressure control. Two team-based approaches are being tested: 1) a medical model of remote BP management (RBPM) alone, and 2) RBPM plus a social model with a community health worker (CHW). These 2 strategies are being compared with a standard community screening program with referral to primary care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Community Health Worker (CHW) — Participants will receive the additional support of a Community Health Worker (CHW); specific activities include: support with home BP monitoring, reminders to attend RBPM clinical visits, and support with social issues impacting health (e.g., food insecurity; transportation; housing instability).
  • Other: Remote Blood Pressure (BP) Management Program (RBPM) — Participants will receive a medical model of remote BP management (RBPM). Care is guided by protocols based on ACC/AHA High Blood Pressure Guidelines. This may include medications and/or lifestyle modifications, as is clinically indicated and personalized to each participant using principles of shared decision making.

Primary Outcomes

  • Blood Pressure Control (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-14
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1440 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Erica Spatz, MD (PRINCIPAL_INVESTIGATOR) - Yale University
  • Rafael Perez-Escamilla, MD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Bonnie Garmisa, MAT
(203) 640-2684
bonnie.garmisa@yale.edu
Jocelyn Dorney, MPH
708-663-0053
Jocelyn.dorney@yale.edu
Interventions
  • Behavioral: Community Health Worker (CHW) — Participants will receive the additional support of a Community Health Worker (CHW); specific activities include: support with home BP monitoring, reminders to attend RBPM clinical visits, and support with social issues impacting health (e.g., food insecurity; transportation; housing instability).
  • Other: Remote Blood Pressure (BP) Management Program (RBPM) — Participants will receive a medical model of remote BP management (RBPM). Care is guided by protocols based on ACC/AHA High Blood Pressure Guidelines. This may include medications and/or lifestyle modifications, as is clinically indicated and personalized to each participant using principles of shared decision making.
Study Locations (4 sites)
Yale, New Haven, Connecticut 06520 United States
Massachusetts General Brigham Hospital, Boston, Massachusetts 02199 United States
Houston Methodist, Houston, Texas 77030 United States
Sentara Health, Norfolk, Virginia 23502 United States
Eligibility Criteria
Inclusion Criteria: * Elevated BP, defined as an average resting BP of \>=135/85 mmHg based on 3 consecutive blood pressure readings Exclusion Criteria: * People who are pregnant or who plan to become pregnant in the next 6 months at study entry * Those that have end stage renal disease on dialysis * People receiving active chemotherapy
Conditions Post-Concussion Syndrome, Concussion, Br...
Phase PHASE2
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury. These symptoms can interfere with daily functioning, causing difficulty returning to physical activity, work, or school. Previous concussion therapies have not been personalized nor involved direct treatments to the brain itself. The treatment being tested in the present study is a noninvasive, personalized form of brain stimulation, called transcranial magnetic stimulation (TMS). The investigators intend to answer the questions: 1. Does personalized TMS improve brain connectivity after concussion? 2. Does personalized TMS improve avoidance behaviors and chronic concussive symptoms? 3. Do the improvements last up to 2 months post-treatment? 4. Are there predictors of treatment response, or who might respond the best? Participants will undergo 14 total visits to University of California Los Angeles (UCLA): 1. One for the baseline symptom assessments and magnetic resonance imaging (MRI) 2. Ten for TMS administration 3. Three for post-treatment symptom assessments and MRIs Participants will have a 66% chance of being assigned to an active TMS group and 33% chance of being assigned to a sham, or inactive, TMS group. The difference is that the active TMS is more likely to cause functional changes in the brain than the inactive TMS.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Active cTBS — 600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
  • Device: Inactive/Sham cTBS — 600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
  • Behavioral: Imaginal exposure — Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities

Primary Outcomes

  • Central target engagement, modulation, and durability (Change from baseline across all subsequent time points until completion of the study, an average of 4 months)
  • Peripheral target engagement, modulation, and durability (Change from baseline across all subsequent time points until completion of the study, an average of 4 months)
  • Persistent post-concussive symptoms modulation and durability (Change from baseline across all subsequent time points until completion of the study, an average of 4 months)
  • Fear avoidance modulation and durability (Change from baseline across all subsequent time points until completion of the study, an average of 4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-06
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Collaborators: United States Department of Defense
Contact Information
Study Contact:
Kevin Bickart, MD/PhD
(818)392-4614
bickartlab@gmail.com
Kevin Bickart, MD/PhD
UCLA
Kevin Bickart, MD/PhD
UCLA
Interventions
  • Device: Active cTBS — 600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
  • Device: Inactive/Sham cTBS — 600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
  • Behavioral: Imaginal exposure — Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
Study Locations (1 sites)
UCLA, Westwood, Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: * Mild traumatic brain injury (mTBI) defined in accord with the World Health Organization criteria in the last 12 months * age 18-65 at the time of the mTBI * high burden of post-concussive symptoms defined as a score \>=20 on the Rivermead Post-Concussion Symptoms Questionnaire Exclusion Criteria: * objective neurologic deficits * ongoing or prolonged (\>3 months) post-concussive symptoms from a prior mTBI within 2 years of the index injury * history of transcranial magnetic stimulation (TMS) therapy * contraindications for TMS or magnetic resonance imaging (MRI) (e.g., metallic implant other than dental, pacemaker) * severe mental, physical, or medical problems that would impede participation or pose a risk for the planned intervention (e.g., liver, kidney, or heart disease, uncontrolled diabetes or hypertension, malignancy, psychosis, previous seizure, pregnancy) * active alcohol or illicit drug abuse * inability to speak and read English